Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide. / Ohrstrom, Caroline Christfort; Worm, Dorte; Hojager, Anna; Andersen, Ditte; Holst, Jens Juul; Kielgast, Urd Lynge; Hansen, Dorte Lindqvist.

In: Diabetes, Obesity and Metabolism, Vol. 21, No. 9, 2019, p. 2142-2151.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Ohrstrom, CC, Worm, D, Hojager, A, Andersen, D, Holst, JJ, Kielgast, UL & Hansen, DL 2019, 'Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide', Diabetes, Obesity and Metabolism, vol. 21, no. 9, pp. 2142-2151. https://doi.org/10.1111/dom.13796

APA

Ohrstrom, C. C., Worm, D., Hojager, A., Andersen, D., Holst, J. J., Kielgast, U. L., & Hansen, D. L. (2019). Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide. Diabetes, Obesity and Metabolism, 21(9), 2142-2151. https://doi.org/10.1111/dom.13796

Vancouver

Ohrstrom CC, Worm D, Hojager A, Andersen D, Holst JJ, Kielgast UL et al. Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide. Diabetes, Obesity and Metabolism. 2019;21(9):2142-2151. https://doi.org/10.1111/dom.13796

Author

Ohrstrom, Caroline Christfort ; Worm, Dorte ; Hojager, Anna ; Andersen, Ditte ; Holst, Jens Juul ; Kielgast, Urd Lynge ; Hansen, Dorte Lindqvist. / Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide. In: Diabetes, Obesity and Metabolism. 2019 ; Vol. 21, No. 9. pp. 2142-2151.

Bibtex

@article{fe2e490d4ea9424992d617aac7af1fdf,
title = "Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide",
abstract = "Aim To investigate the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide on post-bariatric hypoglycaemia (PBH) after Roux-en-Y gastric bypass. Materials and methods In a randomized crossover study, 11 women who had undergone Roux-en-Y gastric bypass and had documented hypoglycaemia were each evaluated during a baseline period without treatment and during five treatment periods with the following interventions: acarbose 50 mg for 1 week, sitagliptin 100 mg for 1 week, verapamil 120 mg for 1 week, liraglutide 1.2 mg for 3 weeks and pasireotide 300 mu g as a single dose. Treatment effects were evaluated by a mixed-meal tolerance test (MMTT) and, for all treatment periods except pasireotide, by 6 days of continuous glucose monitoring (CGM). Results Treatment with acarbose and treatment with pasireotide both significantly lifted nadir glucose levels (mean +/- SEM 3.9 +/- 0.2 and 7.9 +/- 0.4 vs 3.4 +/- 0.2; P < .03) and reduced time in hypoglycaemia during the MMTTs. Acarbose reduced peak glucose levels and time in hyperglycaemia, whereas pasireotide greatly increased both variables. Acarbose and pasireotide reduced insulin and C-peptide levels, and pasireotide also diminished glucagon-like peptide-1 levels. Sitagliptin lowered nadir glucose values, while verapamil and liraglutide had no effect on hypoglycaemia. During the CGM periods, the treatments had no impact on hypoglycaemia, whereas acarbose and liraglutide reduced hyperglycaemia and glycaemic variability. Conclusions In an experimental setting, treatment with acarbose and pasireotide reduced PBH. Acarbose appears to have an overall glucose-stabilizing effect, whereas pasireotide leads to increased and sustained hyperglyca",
keywords = "bariatric surgery, clinical trial, continuous glucose monitoring, GLP-1, hypoglycaemia",
author = "Ohrstrom, {Caroline Christfort} and Dorte Worm and Anna Hojager and Ditte Andersen and Holst, {Jens Juul} and Kielgast, {Urd Lynge} and Hansen, {Dorte Lindqvist}",
year = "2019",
doi = "10.1111/dom.13796",
language = "English",
volume = "21",
pages = "2142--2151",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "9",

}

RIS

TY - JOUR

T1 - Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide

AU - Ohrstrom, Caroline Christfort

AU - Worm, Dorte

AU - Hojager, Anna

AU - Andersen, Ditte

AU - Holst, Jens Juul

AU - Kielgast, Urd Lynge

AU - Hansen, Dorte Lindqvist

PY - 2019

Y1 - 2019

N2 - Aim To investigate the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide on post-bariatric hypoglycaemia (PBH) after Roux-en-Y gastric bypass. Materials and methods In a randomized crossover study, 11 women who had undergone Roux-en-Y gastric bypass and had documented hypoglycaemia were each evaluated during a baseline period without treatment and during five treatment periods with the following interventions: acarbose 50 mg for 1 week, sitagliptin 100 mg for 1 week, verapamil 120 mg for 1 week, liraglutide 1.2 mg for 3 weeks and pasireotide 300 mu g as a single dose. Treatment effects were evaluated by a mixed-meal tolerance test (MMTT) and, for all treatment periods except pasireotide, by 6 days of continuous glucose monitoring (CGM). Results Treatment with acarbose and treatment with pasireotide both significantly lifted nadir glucose levels (mean +/- SEM 3.9 +/- 0.2 and 7.9 +/- 0.4 vs 3.4 +/- 0.2; P < .03) and reduced time in hypoglycaemia during the MMTTs. Acarbose reduced peak glucose levels and time in hyperglycaemia, whereas pasireotide greatly increased both variables. Acarbose and pasireotide reduced insulin and C-peptide levels, and pasireotide also diminished glucagon-like peptide-1 levels. Sitagliptin lowered nadir glucose values, while verapamil and liraglutide had no effect on hypoglycaemia. During the CGM periods, the treatments had no impact on hypoglycaemia, whereas acarbose and liraglutide reduced hyperglycaemia and glycaemic variability. Conclusions In an experimental setting, treatment with acarbose and pasireotide reduced PBH. Acarbose appears to have an overall glucose-stabilizing effect, whereas pasireotide leads to increased and sustained hyperglyca

AB - Aim To investigate the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide on post-bariatric hypoglycaemia (PBH) after Roux-en-Y gastric bypass. Materials and methods In a randomized crossover study, 11 women who had undergone Roux-en-Y gastric bypass and had documented hypoglycaemia were each evaluated during a baseline period without treatment and during five treatment periods with the following interventions: acarbose 50 mg for 1 week, sitagliptin 100 mg for 1 week, verapamil 120 mg for 1 week, liraglutide 1.2 mg for 3 weeks and pasireotide 300 mu g as a single dose. Treatment effects were evaluated by a mixed-meal tolerance test (MMTT) and, for all treatment periods except pasireotide, by 6 days of continuous glucose monitoring (CGM). Results Treatment with acarbose and treatment with pasireotide both significantly lifted nadir glucose levels (mean +/- SEM 3.9 +/- 0.2 and 7.9 +/- 0.4 vs 3.4 +/- 0.2; P < .03) and reduced time in hypoglycaemia during the MMTTs. Acarbose reduced peak glucose levels and time in hyperglycaemia, whereas pasireotide greatly increased both variables. Acarbose and pasireotide reduced insulin and C-peptide levels, and pasireotide also diminished glucagon-like peptide-1 levels. Sitagliptin lowered nadir glucose values, while verapamil and liraglutide had no effect on hypoglycaemia. During the CGM periods, the treatments had no impact on hypoglycaemia, whereas acarbose and liraglutide reduced hyperglycaemia and glycaemic variability. Conclusions In an experimental setting, treatment with acarbose and pasireotide reduced PBH. Acarbose appears to have an overall glucose-stabilizing effect, whereas pasireotide leads to increased and sustained hyperglyca

KW - bariatric surgery

KW - clinical trial

KW - continuous glucose monitoring

KW - GLP-1

KW - hypoglycaemia

U2 - 10.1111/dom.13796

DO - 10.1111/dom.13796

M3 - Journal article

C2 - 31144430

VL - 21

SP - 2142

EP - 2151

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 9

ER -

ID: 226036319